Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 Phase I Safety and PK Study in Healthy Volunteers
NCT06230588Phase 1Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing TQH3906 with Placebo (2 arms). Primary endpoints: Adverse events (AE) up to 18 days, Serious Adverse Events up to 18 days and 1 more. Started Feb 2024; status: completed.
02
Drugs
TQH3906
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06230588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230588.